Centessa Pharmaceuticals plc completed an acquisition by Eli Lilly and Company via a court-sanctioned scheme of arrangement, making it a wholly owned subsidiary of Lilly. Shareholders of Centessa were entitled to receive $38.00 in cash per share plus one non-transferable contingent value right (CVR) entitling them to receive up to $9.00 per share in contingent cash payments based on milestones. The company's Nasdaq delisting and termination of its existing loan and security agreement were also part of the transaction. Centessa Pharmaceuticals plc is a biotechnology company focused on developing clinical-stage therapeutic solutions.

Centessa Pharmaceuticals plc shareholders approved the Scheme of Arrangement and Company Shareholder Resolution to facilitate the acquisition by LDH XV Corporation, a subsidiary of Eli Lilly and Company. The Scheme Proposal received 126,653,456 votes in favor and 23,007 against, meeting the required 75% value threshold. Centessa Pharmaceuticals plc is a biotechnology company focused on developing clinical-stage drug candidates.